CN102153508A - 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone and application of the 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone in preparing antitumour drugs - Google Patents
3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone and application of the 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone in preparing antitumour drugs Download PDFInfo
- Publication number
- CN102153508A CN102153508A CN 201010299621 CN201010299621A CN102153508A CN 102153508 A CN102153508 A CN 102153508A CN 201010299621 CN201010299621 CN 201010299621 CN 201010299621 A CN201010299621 A CN 201010299621A CN 102153508 A CN102153508 A CN 102153508A
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- ketone
- dibenzylidene
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 10
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 8
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 8
- 201000000849 skin cancer Diseases 0.000 claims abstract description 8
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 33
- -1 methoxyl group Chemical group 0.000 claims description 15
- 201000007270 liver cancer Diseases 0.000 claims description 13
- 208000014018 liver neoplasm Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 201000008261 skin carcinoma Diseases 0.000 claims description 7
- 201000000498 stomach carcinoma Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 241000790917 Dioxys <bee> Species 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 150000003934 aromatic aldehydes Chemical class 0.000 abstract description 18
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- NIVYQYSNRUIFIF-KAVGSWPWSA-N (3e,5e)-3,5-bis[(2-fluorophenyl)methylidene]piperidin-4-one Chemical compound FC1=CC=CC=C1\C=C(/CNC\1)C(=O)C/1=C/C1=CC=CC=C1F NIVYQYSNRUIFIF-KAVGSWPWSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- DTUJRJIWGWTNFQ-UHFFFAOYSA-N 1-cyclopropylpiperidin-4-one Chemical compound C1CC(=O)CCN1C1CC1 DTUJRJIWGWTNFQ-UHFFFAOYSA-N 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 208000018706 hematopoietic system disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 0 **(CC(C1=O)=C*)CC1=CN Chemical compound **(CC(C1=O)=C*)CC1=CN 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IAJBQAYHSQIQRE-UHFFFAOYSA-N 2,4,5-trimethoxybenzaldehyde Chemical group COC1=CC(OC)=C(C=O)C=C1OC IAJBQAYHSQIQRE-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- UUAGGAJETHPORG-UHFFFAOYSA-N C(C1)C1N(CCCC1)C1=C1C=CC2=CC=CC=C2C1 Chemical compound C(C1)C1N(CCCC1)C1=C1C=CC2=CC=CC=C2C1 UUAGGAJETHPORG-UHFFFAOYSA-N 0.000 description 1
- XYIMUBJXPVXFMF-UHFFFAOYSA-N CCC(C)N(CC1)CCC1=O Chemical compound CCC(C)N(CC1)CCC1=O XYIMUBJXPVXFMF-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- DNAVOCNYHNNEQI-UHFFFAOYSA-N asaronaldehyde Natural products COC1=CC(OC)=C(C=CC=O)C=C1OC DNAVOCNYHNNEQI-UHFFFAOYSA-N 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical group O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone and application of the 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone in preparing antitumor drugs. The 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compound can be obtained by Claisen-Schimidt reaction of aromatic aldehyde and N-cyclopropyl-4-piperidine ketone. The 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compound can obviously restrain the proliferation of various tumor cells and can be used for preparing drugs for treating leukocythemia, colorectal cancer, lover cancer, skin cancer, gastric cancer, breast cancer, prostatic cancer or other malignant tumor.
Description
Technical field:
The present invention relates to synthesizing antineoplastic medicament and preparation method, be specifically related to synthesize 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds and the application that is used to prepare antitumor drug thereof.
Background technology:
With the 4-piperidone is that intermediate and aromatic aldehyde condensation obtain a series of compounds and have antitumor, anti-inflammatory, antibiotic isoreactivity, and wherein representation compound EF-24 (structural formula is as follows) inside and outside has better antitumor activity [document
1,2].But bibliographical information 3 is not arranged at present, the synthetic and application in preparation treatment antitumor drug of 5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds.
The chemical structural formula of EF-24
Reference
1.Subramaniam?D，May?R，Sureban?SM，et?al.Diphenyl?difluoroketone：a?curcumin?derivative?with?potent?in?vivo?anticancer?activity.[J].Cancer?Res.，2008，68(6)：1962-1969.
2.Adams?BK，Ferstl?EM，Davis?MC，etal.Synthesis?and?biological?evaluation?ofnovel?curcumin?analogs?as?anti-cancer?and?anti-angiogenesis?agents[J].Bioorg?Med?Chem，2004，12(14)：3871-3883.
Summary of the invention:
It is a kind of 3 that one of purpose of the present invention is to provide, 5-(E)-dibenzylidene-N-cyclopropyl piperidine 4-ketone compound.
Of the present invention 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compound general formula is as follows:
The present invention also can adopt and contain 3 of treatment significant quantity, and 5-(E)-dibenzylidene-N-cyclopropyl piperidine 4-ketone compounds and pharmaceutically acceptable carrier are formed composition.The group of the Ar representative in the formula (I) is: substituted-phenyl or heterocycle, the substituting group on the phenyl can be R
1, R
2, R
3, R
4, R
5In at least one non-hydrogen substituting group, if be hydrogen entirely, substituted-phenyl is phenyl (seeing embodiment 7), and two substituting groups such as R are perhaps arranged
1, R
3, also can three substituting group such as R
3, R
4, R
5, five substituent R can be arranged at most
1, R
2, R
3, R
4, R
5, R
1, R
2, R
3, R
4, R
5Can be that identical group also can be different group, as can R
1=R
2, also can, R
1≠ R
2, described substituting group preferred alkyl, alkoxyl group, halogen, haloalkyl or nitro, methoxyl group most preferably, the alkyl of 1-4 carbon, fluorine, trifluoromethyl or nitro; Substituting group on the most preferred phenyl is 2-methoxyl group (seeing embodiment 5); 2,5-dimethoxy (seeing embodiment 4); 3,4-dimethoxy (seeing embodiment 3); 2,4,5-trimethoxy (seeing embodiment 1); 2-fluorine (seeing embodiment 2); 2-chlorine (seeing embodiment 9); 2-bromine (seeing embodiment 8); 4-methyl (seeing embodiment 12); 2-trifluoromethyl (seeing embodiment 6); 3,4-methylene dioxy base (seeing embodiment 10); Substituted-phenyl Ar is 2-naphthylidene (seeing embodiment 11).The preferred pyridyl of described heterocycle, pyrryl or furyl, most preferably 3-pyridyl.
Two of the object of the invention is to provide 3, the preparation method of 5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds.Compound 3 of the present invention, 5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compound can carry out the Claisen-Schimidt reaction by aromatic aldehyde and N-cyclopropyl-4-piperidone and obtain.Reaction equation is schematically as follows:
Three of the object of the invention is to provide 3, the application of the composition of 5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds and composition thereof in the preparation antitumor drug.
Of the present invention 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds can be used for but is not limited to medicine as preparation treatment leukemia, colorectal carcinoma, skin carcinoma, cancer of the stomach, liver cancer, mammary cancer or prostate cancer.
The invention provides and be used for the treatment of antitumor medicine composition, wherein contain compound any in the claim 1～5 for the treatment of significant quantity and pharmaceutically acceptable carrier.Described treatment significant quantity is the minimum dose that result of treatment is arranged on the pharmacology clinically.
The invention provides the pharmaceutical composition that is used for the treatment of from blood disease, colorectal carcinoma, skin carcinoma, cancer of the stomach, liver cancer, mammary cancer, prostate cancer, wherein contain compound any in the claim 1～5 for the treatment of significant quantity and pharmaceutically acceptable carrier.Described treatment significant quantity is the minimum dose that result of treatment is arranged on the pharmacology clinically.
According to embodiment of the present invention, 3 of treatment cancer of the present invention, the medicine or the composition of 5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds, the example of treatable cancer is including, but not limited to from blood disease, colorectal carcinoma, skin carcinoma, cancer of the stomach, liver cancer, mammary cancer, prostate cancer.
Beneficial effect of the present invention is: of the present invention 3, the external propagation that can significantly suppress the various human tumour cell of 5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone one compounds sees Table 1; Oral administration is that example adds 100mgKg with compound 2 in the body
-1D
-1Amount can be to H22 liver cancer transplanted tumor mouse inhibitory rate 48.4%, see Table 2, Fig. 1, illustrate of the present inventionly 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds can be used for as the medicine of preparation treatment from blood disease, colorectal carcinoma, liver cancer, skin carcinoma, cancer of the stomach, mammary cancer or prostate cancer etc.
And preparation method of the present invention is different with the EF-24 compounds process for production thereof in the background technology, the EF-24 compounds process for production thereof can not be used for preparation of the present invention, EF-24 is synthetic to be to make catalyzer and reaction solvent with the Glacial acetic acid of saturated HCl etc., and the reaction times is generally 2d.Target compound 3 of the present invention, 5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone is to use base catalysis, and ethanol is solvent, and the reaction times obviously shortens, and generally at 30min-1d, separation and purification is simple, and the solvent non-corrosiveness, green safety.The time of the present invention's preparation is short, the usefulness height, and preparation technology is simple, and the yield height reaches more than 60%, can reach 88%.
Description of drawings:
Fig. 1 is the restraining effect figure of 2 couples of mouse H22 of compound of the present invention ascitic type liver cancer transplanted tumor,
That the row of going up is the liver cancer transplanted tumor shape figure that does not add compound 2 among the figure, following row with last row's contrast among the figure is the inhibition shape figure that adds compound 2 back liver cancer transplanted tumors, and mouse H22 ascitic type liver cancer transplanted tumors were subjected to obvious inhibition after last figure below was compared and added compound 2 as can be known.
Embodiment:
The present invention is described in detail below in conjunction with embodiment:
Fusing point is used the micro-fusing point instrument of the Nereid X-4 of close instrument plant type and is measured, and temperature is not calibrated.
1H,
13C NMR spectrum adopts Bruker Avance III type nuclear magnetic resonance analyser (400MHz) to measure, and TMS is interior mark.Mass spectrum adopts Agilent 1100LC/MSD Trap ion trap LC-MS instrument to measure.Raw materials used 1-cyclopropyl 4-piperidone, aromatic aldehyde are available from the chemical company limited of A Faaisha (Tianjin), and sodium hydroxide, dehydrated alcohol, concentrated hydrochloric acid, acetic acid are available from traditional Chinese medicines chemical reagents corporation.
3, the synthetic logical method of 5-(E)-dibenzylidene-N-cyclopropyl piperidine 4-ketone
N-cyclopropyl-4-piperidone 348mg (2.5mmol), sodium hydroxide 20mg (0.5mmol), dehydrated alcohol 20mL mixes the back stirring at room, waits to clarify the back and adds aromatic aldehyde (5mmol), reacts 0.5h～24h under the room temperature, has solid to separate out.Suction filtration, filter cake absolute ethanol washing, vacuum-drying.The various aromatic aldehydes that adopted in this example (its mole number is 5mmol), referring to as follows: the chemical structural formula of embodiment one～12 synthetic 1～12 compound is as follows:
Be 1-12 kind 3, the chemical structural formula of 5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds is:
1-12 kind 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds is measured through fusing point instrument, nuclear magnetic resonance analyser and mass spectrograph, and its measured value is as follows:
Embodiment one, when aromatic aldehyde is asarylaldehyde, make 3,5-(E)-two (2,4,5-trimethoxy benzylidene)-N-cyclopropyl piperidine-4-ketone (compound 1) is the orange powder, yield 60%, mp150～153 ℃, ESI-MS:496.3 (M+1);
1H-NMR (CDCl
3, ppm) δ: 8.02 (2H, s ,-CH=), 6.82 (2H, s, Ar-H), 6.55 (2H, s, Ar-H), 4.63 (4H, s ,-CH
2-), 3.86 (18H, s ,-OCH
3), 1.93 (s, 1H ,-N-CH (CH
2)
2), 0.44-0.39 (m, 4H ,-CH (CH
2)
2). δ: 87.99,154.18,151.13,142.54,131.93,116.36,114.32,109.17,97.27,56.86,56.35,56.21,55.19,37.42,6.67
Embodiment two, when aromatic aldehyde is the 2-fluorobenzaldehyde, make 3,5-(E)-two (2-fluorine benzylidene)-N-cyclopropyl piperidine-4-ketone (compound 2) is pale yellow powder, yield 88%, mp169～172 ℃, ESI-MS:352.3 (M+1);
1H-NMR (CDCl
3, ppm) δ: 7.88 (2H, s ,-CH=), 7.39～7.31 (4H, m, Ph-H), 7.22～7.11 (4H, m, Ph-H), 3.86 (s, 4H ,-CH
2-), 1.90 (s, 1H ,-N-CH (CH
2)
2), 0.47-0.40 (m, 4H ,-CH (CH
2)
2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 186.71,162.22,159.72,135.09,130.76,129.25,123.99,123.25,115.82,54.98,37.70,6.77.
Embodiment three, when aromatic aldehyde is 3, during the 4-dimethoxy benzaldehyde, make 3,5-(E)-two (3, the 4-dimethoxybenzylidenegroup group)-N-cyclopropyl piperidine-4-ketone (compound 3) is yellow powder, yield 66%, mp195～198 ℃, ESI-MS:436.3 (M+1);
1H-NMR (CDCl
3, ppm) δ: 7.75 (2H, s ,-CH=), 7.06 (2H, d, J=8Hz, Ar-H), 6.97 (2H, s, Ar-H), 6.93 (2H, d, J=8Hz, Ar-H), 4.01 (4H, s ,-CH
2-), 3.92 (12H, s ,-OCH
3), 1.97 (s, 1H ,-N-CH (CH
2)
2), 0.53-0.48 (m, 4H ,-CH (CH
2)
2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 187.16,150.01,148.86,136.26,128.40,124.04,123.89,114.04,111.13,55.99,55.75,55.12,37.90,6.73
Embodiment four, when aromatic aldehyde is 2, during the 5-dimethoxy benzaldehyde, make 3,5-(E)-two (2, the 5-dimethoxybenzylidenegroup group)-N-cyclopropyl piperidine-4-ketone (compound 4) is golden yellow powder, yield 77%, mp138～141 ℃, ESI-MS:436.3 (M+1);
1H-NMR (CDCl
3, ppm) δ: 7.99 (2H, s ,-CH=), 6.91-6.84 (4H, m, Ar-H), 6.81 (2H, s, Ar-H), 3.89 (4H, s ,-CH
2-), 3.80 (12H, s ,-OCH
3), 1.89 (s, 1H ,-N-CH (CH
2)
2), 0.43-0.37 (m, 4H ,-CH (CH2) 2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 187.43,152.99,152.96,133.70,132.14,125.38,116.34,114.88,111.89,56.17,55.87,55.05,37.59,6.77
Embodiment five, when aromatic aldehyde is the 2-dimethoxy benzaldehyde, make 3,5-(E)-two (2-methoxyl group benzylidene)-N-cyclopropyl piperidine-4-ketone (compound 5) is faint yellow needle-like crystal, yield 80%, mp178～181 ℃, ESI-MS:476.3 (M+1);
1H NMR (CDCl
3, ppm) δ: 8.05 (2H, s ,-CH=), 7.36 (2H, t, J=8Hz, Ar-H), 7.25 (2H, d, J=8Hz, Ar-H), 6.99 (2H, t, J=8Hz, Ar-H), 6.92 (2H, d, J=8Hz, Ar-H), 3.88 (4H, s ,-CH
2-), 3.85 (6H, s ,-OCH
3), 1.88 (s, 1H ,-N-CH (CH
2)
2), 0.42-0.35 (m, 4H ,-CH (CH
2)
2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 187.56,158.52,133.40,132.19,130.39,130.31,124.63,120.09,110.82,55.52,55.15,37.67,6.72
Embodiment six, when aromatic aldehyde is the 2-trifluoromethylated benzaldehyde, make 3,5-(E)-two (2-trifluoromethyl benzylidene)-N-cyclopropyl piperidine-4-ketone (compound 6) is yellow needle, yield 60%, mp152～154 ℃, ESI-MS:452.3 (M+1);
1H-NMR (400MHz, CDCl
3, ppm) δ: 8.04 (2H, s ,-CH=), 7.75 (2H, d, Ph-H, J=7.6Hz), 7.59 (2H, t, Ph-H, J=7.6Hz), 7.48 (2H, t, Ph-H, J=7.6Hz), 7.30 (2H, d, Ph-H, J=7.6Hz), 3.73 (s, 4H ,-CH
2-), 1.86 (s, 1H ,-N CH (CH
2)
2), 0.39-0.33 (m, 4H ,-CH (CH
2)
2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 186.11,162.22,159.72,135.09,130.76,129.25,123.99,123.25,115.82,54.05,36.65,6.62.
Embodiment seven, when aromatic aldehyde is phenyl aldehyde, make 3,5-(E)-two (2-benzylidene)-N-cyclopropyl piperidine-4-ketone (compound 7), pale yellow powder, yield 80%, 156～159 ℃ of mp, ESI-MS:316.3 (M+1);
1H-NMR (400MHz, CDCl
3, ppm) δ 7.80 (2H, s ,-CH=), 7.46～7.35 (10H, m, Ph-H), 3.99 (s, 4H ,-CH
2-), 1.97～1.92 (m, 1H ,-N-CH (CH
2)
2), 0.50-0.38 (m, 4H ,-CH (CH
2)
2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 187.54,136.26,135.37,133.50,13 0.49,128.97,128.59,128.23,127.25,55.18,38.03,6.81
Embodiment eight, when aromatic aldehyde is the 2-bromobenzaldehyde, make 3,5-(E)-two (2-bromine benzylidene)-N-cyclopropyl piperidine 4-ketone (compound 8), yellow powder, yield 77%, mp130～135 ℃, ESI-MS:492.3 (M+1);
1H-NMR (400MHz, CDCl
3, ppm) δ: 7.94 (2H, s ,-CH=), 7.66 (2H, d, Ph-H, J=8Hz), 7.37 (2H, t, Ph-H, J=7.6Hz), 7.27～7.21 (4H, q, Ph-H, J=7.2Hz), 3.82 (s, 4H ,-CH
2-), 1.88 (s, 1H ,-N-CH (CH
2)
2), 0.44-0.37 (m, 4H ,-CH (CH
2)
2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 186.81,136.30,135.52,134.25,133.19,130.32,130.09,127.10,125.24,54.51,37.49,6.74
Embodiment nine, when aromatic aldehyde is the 2-chlorobenzaldehyde, make 3,5-(E)-two (2-chlorine benzylidene)-N-cyclopropyl piperidine 4-ketone (compound 9), pale yellow powder, yield 74%, 152～155 ℃ of mp, ESI-MS:384.3 (M+1);
1H-NMR (400MHz, CDCl
3, ppm) δ: 7.99 (2H, s ,-CH=), 7.34～7.26 (8H, m, Ph-H), 3.83 (s, 4H ,-CH
2-), 1.88 (m, 1H ,-N-CH (CH
2)
2), 0.45-0.35 (m, 4H ,-CH (CH
2)
2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 186.81,135.21,134.63,133.89,133.74,130.34,129.97,129.95,126.47,54.67,37.58,6.76
Embodiment ten, when aromatic aldehyde is piperonylaldehyde, make 3,5-(E)-two (3,4-methylene dioxy base benzylidene)-N-cyclopropyl piperidine-4-ketone (compound 10), yellow powder, yield 68%, mp215～218 ℃, ESI-MS:404.3 (M+1);
1H-NMR (400MHz, CDCl
3, ppm) δ: 7.68 (2H, s ,-CH=), 6.97 (2H, d, Ph-H, J=8Hz), 6.93 (2H, s, Ph-H), 6.88 (2H, d, Ph-H, J=8Hz), 6.03 (4H, s, O-CH2-O), 3.94 (s, 4H ,-CH
2-), 1.95 (m, 1H ,-N-CH (CH
2)
2), 0.54-0.40 (m, 4H ,-CH (CH
2)
2).
13C-NMR(100MHz，CDCl
3，ppm)δ：187.24，148.38，147.91，135.93，132.02，129.62，126.09，110.06，108.61，101.48，55.26，38.14，6.87
Embodiment 11, when aromatic aldehyde is the 2-naphthaldehyde, make 3,5-(E)-two (2-naphthylidene)-N-cyclopropyl piperidine 4-ketone (compound 11), pale yellow powder, yield 82%, 199～202 ℃ of mp, ESI-MS:416.3 (M+1);
1H-NMR (400MHz, CDCl
3, ppm) δ: 7.99 (2H, s ,-CH=), 7.92～7.98 (4H, m, Ph-H), 7.88～7.85 (4H, m, Ph-H), 7.56～7.51 (6H, m, Ph-H), 4.14 (s, 4H ,-CH
2-), 2.02 (m, 1H ,-N-CH (CH
2)
2), 0.50-0.40 (m, 4H ,-CH (CH
2)
2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 136.61,133.76,133.26,133.14,132.93,130.58,128.58,128.23,127.72,127.50,127.13,126.58,55.19,37.91,6.85
Embodiment 12, when aromatic aldehyde is the 4-tolyl aldehyde, make 3,5-(E)-two (4-methyl benzylidene)-N-cyclopropyl piperidine-4-ketone (compound 12), pale yellow powder, yield 88%, 196～199 ℃ of mp, ESI-MS:344.3 (M+1);
1H-NMR (400MHz, CDCl
3, ppm) δ: 7.76 (2H, s ,-CH=), 7.33 (4H, d, Ph-H, J=8Hz), 7.24 (4H, d, Ph-H, J=8Hz), 3.99 (s, 4H ,-CH
2-), 2.40 (s, 6H, Ph-CH
3) 1.95 (m, 1H ,-N-CH (CH
2)
2), 0.45-0.35 (m, 4H ,-CH (CH
2)
2).
13C-NMR (100MHz, CDCl
3, ppm) δ: 187.49,139.27,136.22,132.78,132.62,130.60,129.36,55.22,38.01,21.45,6.78
Embodiment 13
The detection of anti tumor activity in vitro:
The tumor cell line that uses has: human acute transformation of chronic myelocytic leukemia cell K562, and people's promyelocytic leukemia cell HL60, human colon cancer cell SW480, human colon cancer cell SW1116, above cell all derive from Chinese Academy of Sciences's Shanghai cell bank.
Cell cultures in the RPMI1640 that adds 10% calf serum cultivates, at 37 ℃, 5%CO
2Cultivate in the incubator, take the logarithm vegetative period cell be used for the experiment.
Some amount is in the cell of logarithmic phase, be inoculated in (attached cell is treated adherent back) in 96 orifice plates by certain density, what experimental group added different concns respectively is subjected to the reagent thing, control group adds with the concentration solvent, other establishes blank group and (only adds substratum, acellular), establish three parallel holes for every group, cultivate 48h for 37 ℃, add the MTT solution 20ul/ hole of 5mg/ml, after continuing to cultivate 4h, the centrifugal supernatant of abandoning adds DMSO 150ul, vibration 10min, fully after the cracking, detect absorbancy (OD570) value at 570nm place with full-automatic microplate reader (production of U.S. BIO-RAD company).Calculate inhibitory rate of cell growth according to absorbancy.Inhibitory rate of cell growth=[OD contrast-OD experiment]/[OD contrast-OD blank] * 100%.
To the mapping of growth of tumour cell inhibiting rate, can obtain dose response curve with the different concns of same medicine, obtaining this medicine cell growth inhibiting rate according to equation of linear regression is that 50% concentration is half-inhibition concentration IC
50The results are shown in Table 1, the compound number 1～12 in the table 1 is represented embodiment one～12 a synthetic compound, and EF-24 is as contrast.As can be seen from Table 1,2 pairs of HL60 cell inhibitory activities of compound are stronger than EF-24,7 pairs of K562 cell inhibitory activities of compound are stronger than EF-24, compound 3,9 pairs of SW1116 cell inhibitory activities of compound are stronger than EF-24, illustrate 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds can significantly suppress the propagation of various human tumour cell.Protection scope of the present invention is not limited only to above-described embodiment.
Table 13,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone compounds is to the IC of cultured tumor cells in vitro
50(μ molL
-1)
| Compound number | K562 | HL60 | SW480 | SW1116 |
| 1 | 12.5 | 33.6 | 134 | 49.5 |
| 2 | 4.22 | 5.13 | 25.8 | 17.25 |
| 3 | 8.90 | ? | ? | 2.60 |
| 4 | 18.6 | 19.7 | 32.3 | 14.9 |
| 5 | 17.8 | 44.0 | 49.1 | 35.6 |
| 6 | 24.0 | ? | ? | 38.6 |
| 7 | 0.559 | ? | ? | 74.0 |
| 8 | 6.86 | ? | ? | 14.1 |
| 9 | 14.2 | ? | ? | 10.4 |
| 10 | 37.2 | ? | ? | 61.0 |
| 11 | 412 | ? | ? | 89.6 |
| 12 | 417 | ? | ? | 37.9 |
| EF-24 | 1.58 | 11.2 | 10.0 | 11.7 |
* the space is that compound is not done this cell strain
The influence of 2 couples of mouse H22 of embodiment ten Four Modernizations compounds ascites hepatoma cells growth
Inoculated tumour cell according to a conventional method: get the abdominal cavity well-grown oyster white ascites of 6～8d that goes down to posterity, be diluted to 1 * 10 with physiological saline
7Individual/mL, it is subcutaneous to be inoculated in the right armpit of mouse with 0.2mL, inoculation back animal random packet.Experiment is divided into 2 groups, and 10 every group, negative control group (giving the equivalent solvent), compound 2100mg/kg organize (compound 2 usefulness poloxamers are prepared into solid dispersion).Gastric infusion behind inoculation 24h, once a day, continuous 7d.Weigh in 8d, animal is put to death in the cervical vertebra dislocation.Peel off tumor tissues, weigh after blotting with filter paper.Calculate tumor control rate.
Tumour inhibiting rate=(1-experimental group knurl weight/negative control group knurl is heavy) * 100%
The restraining effect of 2 couples of mouse H22 of compound ascitic type subcutaneous transplantation knurl is obvious, and the inhibiting rate that 100mg/kg/d irritates stomach is 48.4%, and difference has significance (P＜0.01) (the results are shown in Table 2, Fig. 1).
The restraining effect of 2 couples of mouse H22 of table 2 compound ascitic type liver cancer transplanted tumor
**：p＜0.01，*：p＜0.05?vs?control.t?test
Claims (10)
1. the compound of following general formula (I):
Wherein:
Substituent R on the phenyl in the following formula
1, R
2, R
3, R
4, R
5In have one at least for non-hydrogen substituting group; Perhaps R
1, R
2, R
3, R
4, R
5Be hydrogen.
2. compound according to claim 1 is characterized in that having at least on the phenyl substituting group, and described substituting group has at least one to be selected from alkyl, alkoxyl group, halogen, haloalkyl or nitro substituent.
3. compound according to claim 1 is characterized in that heterocycle is pyridyl or pyrryl or furyl, preferred 3-pyridyl.
4. compound according to claim 1 and 2 is characterized in that the substituting group on the phenyl has alkyl, fluorine, chlorine, bromine substituent, trifluoromethyl or a nitro that is selected from methoxyl group, a 1-4 carbon at least.
5. compound according to claim 1 and 2 is characterized in that the substituting group on the phenyl is the 2-methoxyl group; 2, the 5-dimethoxy; 3, the 4-dimethoxy; 2,4, the 5-trimethoxy; The 2-fluorine; 2-chlorine; The 2-bromine; The 4-methyl; The 2-trifluoromethyl; 3,4-methylene dioxy base; Substituted-phenyl Ar is the 2-naphthylidene.
6. be used for the treatment of antitumor medicine composition, wherein contain compound any in the claim 1～5 for the treatment of significant quantity and pharmaceutically acceptable carrier.
7. the pharmaceutical composition that is used for the treatment of leukemia, colorectal carcinoma, skin carcinoma, cancer of the stomach, liver cancer, mammary cancer, prostate cancer wherein contains compound any in the claim 1～5 for the treatment of significant quantity and pharmaceutically acceptable carrier.
8. any one compound in the claim 1～5, the application in the preparation antitumor drug.
9. any one compound in the claim 1～5, the application in preparation treatment leukemia, colorectal carcinoma, skin carcinoma, cancer of the stomach, liver cancer, mammary cancer, prostate cancer medicine.
10. the described pharmaceutical composition of claim 6 is preparing the application for the treatment of in leukemia, colorectal carcinoma, skin carcinoma, cancer of the stomach, liver cancer, mammary cancer, the prostate cancer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010299621 CN102153508B (en) | 2010-10-08 | 2010-10-08 | 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone and application of the 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone in preparing antitumour drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010299621 CN102153508B (en) | 2010-10-08 | 2010-10-08 | 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone and application of the 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone in preparing antitumour drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102153508A true CN102153508A (en) | 2011-08-17 |
| CN102153508B CN102153508B (en) | 2013-01-09 |
Family
ID=44435225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010299621 Expired - Fee Related CN102153508B (en) | 2010-10-08 | 2010-10-08 | 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone and application of the 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone in preparing antitumour drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102153508B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106083704A (en) * | 2016-06-06 | 2016-11-09 | 福建医科大学 | 3,5 (E) two aryl methylene N cyclopropyl piperidine 4 ketone compounds is as the application of Hsp90 inhibitor |
| WO2020047186A1 (en) * | 2018-08-29 | 2020-03-05 | Baylor College Of Medicine | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents |
| US11312676B2 (en) | 2014-12-30 | 2022-04-26 | Baylor College Of Medicine | Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer |
| CN114907189A (en) * | 2021-02-10 | 2022-08-16 | 杭州师范大学 | Polyphenol-substituted 3-aryl-2-aryl methacrylic compound and preparation method and application thereof |
| CN114907190A (en) * | 2021-02-10 | 2022-08-16 | 杭州师范大学 | Polyphenol compound based on meta-substituted phenol and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101434600A (en) * | 2008-12-25 | 2009-05-20 | 福建医科大学 | Curcumin piperidone analog and use thereof in anti-tumor medicament |
-
2010
- 2010-10-08 CN CN 201010299621 patent/CN102153508B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101434600A (en) * | 2008-12-25 | 2009-05-20 | 福建医科大学 | Curcumin piperidone analog and use thereof in anti-tumor medicament |
Non-Patent Citations (1)
| Title |
|---|
| 《中国药物化学杂志》 20091031 刘洋 等 3, 5-二亚苄基哌啶- 4-酮类化合物的合成及其体外抗肿瘤活性 全文 1-10 第19卷, 第5期 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11312676B2 (en) | 2014-12-30 | 2022-04-26 | Baylor College Of Medicine | Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer |
| CN106083704A (en) * | 2016-06-06 | 2016-11-09 | 福建医科大学 | 3,5 (E) two aryl methylene N cyclopropyl piperidine 4 ketone compounds is as the application of Hsp90 inhibitor |
| CN106083704B (en) * | 2016-06-06 | 2018-07-27 | 福建医科大学 | Application of-two aryl methylene-N- cyclopropyl piperidine -4- ketone compounds of 3,5- (E) as Hsp90 inhibitor |
| JP2021534221A (en) * | 2018-08-29 | 2021-12-09 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | How to use the steroid receptor coactivator-3 as a small molecule stimulator and as a cardioprotector and / or revascularizer |
| US20210115017A1 (en) * | 2018-08-29 | 2021-04-22 | Baylor College Of Medicine | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents |
| CN112955217A (en) * | 2018-08-29 | 2021-06-11 | 贝勒医学院 | Small molecule stimulators of steroid receptor co-activator-3 and methods of their use as cardioprotective and/or revascularizing agents |
| US10875841B2 (en) | 2018-08-29 | 2020-12-29 | Baylor College Of Medicine | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents |
| WO2020047186A1 (en) * | 2018-08-29 | 2020-03-05 | Baylor College Of Medicine | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents |
| US11708350B2 (en) | 2018-08-29 | 2023-07-25 | Baylor College Of Medicine | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents |
| US20230357200A1 (en) * | 2018-08-29 | 2023-11-09 | Baylor College Of Medicine | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents |
| JP7495138B2 (en) | 2018-08-29 | 2024-06-04 | ベイラー カレッジ オブ メディスン | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or revascularizing agents - Patents.com |
| CN114907189A (en) * | 2021-02-10 | 2022-08-16 | 杭州师范大学 | Polyphenol-substituted 3-aryl-2-aryl methacrylic compound and preparation method and application thereof |
| CN114907190A (en) * | 2021-02-10 | 2022-08-16 | 杭州师范大学 | Polyphenol compound based on meta-substituted phenol and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102153508B (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101003470B (en) | Analog of mono carbonyl structure of curcumin, and usage | |
| CN105254615B (en) | Phenylaminopyrimidine derivatives and their use in preparation of drugs for resisting cancers | |
| CN102153508B (en) | 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone and application of the 3,5-(E)-dibenzylidene-N-cyclopropyl piperidine-4-ketone in preparing antitumour drugs | |
| CN101434600B (en) | Curcumin piperidone analog and use thereof in anti-tumor medicament | |
| CN106083704B (en) | Application of-two aryl methylene-N- cyclopropyl piperidine -4- ketone compounds of 3,5- (E) as Hsp90 inhibitor | |
| CN106674242B (en) | A kind of curcuma zedoary 01 derivatives with anti-tumor activity and its preparation method and application | |
| CN106220631B (en) | A kind of 7 fluorine replace Isaindigotone derivative and preparation method thereof and are preparing the application in anticancer drug | |
| CN109467565B (en) | Dihydroartemisinin trimer and preparation method and application thereof | |
| CN101691353A (en) | N-Boc-3,5-(E)-diarylidene-4-piperidone and application thereof in preparation of anti-tumor drugs | |
| CN101332198B (en) | Pharmaceutical use of 6-aryl-3-substituted carbonyl pyridine compound | |
| CN109516926B (en) | Preparation and application of piperlonguminine derivative | |
| CN101434525A (en) | 4-(4-hydroxy3-methoxybenzene methyl) curcumin and use thereof in preparing anti-tumor medicament | |
| CN103130632A (en) | 1-substituted benzylidene-2-naphthalenone derivative, preparation method thereof and use thereof | |
| CN103435560B (en) | Synthesis and application of aceanthrylene [1,2-b] quinoxaline derivative with flexible side chain | |
| CN101434524B (en) | 4-(4-hydroxy-3-methoxybenzene methylene) curcumin, preparation thereof and use in preparing anti-cancer medicament | |
| CN110698512B (en) | Tin complex with 2-acetylpyridine thiosemicarbazone as ligand and synthesis method thereof | |
| CN110156816B (en) | Tetrahydropyrazolopiperazine compound and preparation method and application thereof | |
| CN112920149A (en) | Chiral dihydropyran ring derivative and preparation method and application thereof | |
| CN106543155B (en) | Chalcone and flavonoid derivative as aurora kinase inhibitor | |
| CN111454232B (en) | 1,3, 4-thiadiazine compound and application thereof | |
| CN113004268B (en) | Thiazole compound for inhibiting tumor cell growth and application thereof | |
| CN109942566A (en) | Isonicotinic acid derivatives and its preparation method and application | |
| KR101540033B1 (en) | A novel benzochalcones and composition for anticancer comprising the same | |
| CN115611930B (en) | Novel zinc (II) complex with high anticancer activity, and preparation method and application thereof | |
| CN107652275A (en) | Quinazoline derivant and its production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130109 |